SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Dec. 22, 1998-- Shaman Pharmaceuticals, Inc. (Nasdaq:SHMN) announced today favorable results from their single pivotal Phase III study of SP-303/Provir(tm) for the treatment of diarrhea in people with AIDS. The double-blind, randomized, placebo-controlled trial was divided
DURHAM, N.C.--(BW HealthWire)--Dec. 14, 1998--Trimeris, Inc. (NASDAQ: TRMS - news) announced today that preliminary findings from TRI-002, a Phase II study of T-20, a member of a new class of anti-HIV compounds known as fusion inhibitors, will be presented at the International Conference on the Discovery and Clinical D
HOFFMAN ESTATES, Ill.--(BUSINESS WIRE)--Dec. 10, 1998--Home Access Health Corporation, which markets the nation s only FDA-approved anonymous, at-home telemedicine HIV counseling and testing service, today applauded the new recommendations from the Centers for Disease Control and Prevention (CDC) calling for states to
NEWTOWN, Pa.--(BW HealthWire)--Dec. 7, 1998--Key facts about HIV and AIDS are available from Scott-Levin s quarterly HIV Therapy Audit, which projects data from general and family practitioners, internists, and infectious disease specialists who are actively treating HIV patients. While the U.S. Centers for Disease Con
LENEXA, Kan.--(BW HealthWire)--Dec. 3, 1998-- Clinical Reference Laboratory (CRL), one of the country s leading clinical reference laboratories, announced today results of the largest study to date showing a significant proportion of individuals - approximately one out of every 1,000- within the low risk population tes
LA JOLLA, Calif.--(BW HealthWire)--Dec. 1, 1998--La Jolla Diagnostics Inc. (OTC BB:LAJD) announced today that its subsidiary DiagnosTech Inc. has developed a rapid diagnostic test for HIV I & II for mass distribution in Sub-Saharan Africa. According to a joint United Nations, World Health Organization report, a
OAKLAND, Calif--(BUSINESS WIRE)--Nov. 30, 1998--Kaiser Permanente is launching an innovative community outreach program to help East Bay residents with HIV or AIDS better manage their health and live fuller lives an especially useful program in light of Alameda County s recent declaration of a state of emergency for th
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nov. 30, 1998--Vasogen Inc. (ME:VAS) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance to Vasogen for a patent containing claims covering the use of the company s cell therapy for the treatment of autoimmune disease. Based on r
LOS ANGELES--(BUSINESS WIRE)--Nov. 30, 1998--The County of Los Angeles Department of Health Services will commemorate the 10th anniversary of World AIDS Day on Dec. 1, 1998, by announcing the impact of AIDS locally and providing information on the numerous World AIDS Day events and other programs to educate youth about
WHAT: In honor of World AIDS Day 1998, the S.F. AIDS Foundation has debuted a section on its web site (www.sfaf.org) called Remembrance, where members of the community can post memories of loved ones they have lost to AIDS. As we move into a new stage of HIV/AIDS, with advanced treatments prolonging and improving the l
STANFORD, Calif.--(BW HealthWire)--Nov. 24, 1998--Viruses such as the AIDS-causing HIV are parasites: to reproduce, they need to appropriate their host s resources. Stanford researchers have discovered that one of HIV s requirements is a critical cellular protein called NFAT, which allows the virus to multiply in the T
ATLANTA--(BW HealthWire)--Nov. 24, 1998--Research from Durex Global Sex Survey Reveals Alarming Rate of HIV/AIDS Complacency Knowledge does not always result in positive action, especially when it relates to issues of sexual protection. This is one of the alarming findings uncovered by the international 1998 Durex Glob
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Nov. 19, 1998-- Shaman Pharmaceuticals, Inc. (Nasdaq:SHMN) announced today that it has filed a registration statement with the Securities and Exchange Commission ( SEC ) for a private offering of 4,812,071 shares of common stock raising approximately $7.2 million. The commo
PORTLAND, Ore.--(BW HealthWire)--Nov. 18, 1998--AVI BIOPHARMA ( AVI )(Nasdaq: AVII, AVIIW) today announced that Patrick L. Iversen, Ph.D., Vice President of Research and Development of AVI and Thomas Porter, M.D. of the University of Nebraska Medical Center have been awarded a small business technology transfer grant f
STANFORD, Calif.--(BW HealthWire)--Nov. 16, 1998--A unusual mutation, adding two extra building blocks to a key viral protein, enables the AIDS virus to resist multiple drugs, Stanford researchers have found. Patients with this new version of HIV should consider altering their drug regimens, the researchers said. But t
WEST LAFAYETTE, Ind.--(BW HealthWire)--Nov. 16, 1998-- Bioanalytical Systems, Inc. (Nasdaq:BASI) announced today that it has successfully developed a quick and accurate method for concurrently monitoring multiple HIV protease and reverse transcriptase inhibiting drugs in blood samples. The proprietary method is now ava
OLYMPIA, Wash.: A draft rule to require physicians and other providers to report cases of HIV to public health officials will be presented to the State Board of Health today in SeaTac. The rule will help local health departments prevent the spread of the HIV virus, according to Mary Selecky, acting secretary of the Sta
TORONTO--(BUSINESS WIRE)--Oct. 30, 1998--Novopharm Biotech Inc. (TSE:NVO. - news) announced today that it has completed a preliminary report for the Health Protection Branch on the Phase I(a) clinical trial of GPI-2A, the Company s lead antisense oligonucleotide product targeted for the treatment of HIV/AIDS. GPI-2A is
BERKELEY, Calif.--(BUSINESS WIRE)--Oct. 21, 1998--The Chinese National AIDS Center for Prevention and Control announced today that it has begun evaluation of the HIV-1 urine antibody test system produced by Calypte Biomedical (NASDAQ: CALY - news). HIV and AIDS have become major public health issues in
SAN FRANCISCO--(BW HealthWire)--Oct. 15, 1998--An innovative advertising campaign designed to inform gay men about a successful HIV prevention program that counsels and treats people immediately after possible exposure to the AIDS virus was launched today in San Francisco. The new campaign highlights the availability o
SAN FRANCISCO--(BW HealthWire)--Oct. 13, 1998-- Davis Supports More Funds for Education, Research and Treatment; Lungren Advocates Prevention, Early Intervention and Public-Private Partnerships; Complete Survey Results Available at www.sfaf.org If elected Governor of California, Lieutenant Governor Gray Davis would sup
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Oct. 9, 1998-- United Biomedical Inc. (UBI) has developed a monoclonal antibody, termed B4, with the unique properties of neutralizing globally diverse primary isolates of HIV, and protecting animals from HIV infection even when the antibody is administered after infection. UBI is deve
BERKELEY, Calif.--(BUSINESS WIRE)--Oct. 8, 1998--Calypte Biomedical Corporation (NASDAQ:CALY - news) announced today that a total of 20 leading U.S. life insurance companies have begun applicant assessment using Calypte s complete Human Immunodeficiency Virus Type 1 (HIV-1) urine test system. Calypte executives said th
PREVEON Profile to be Highlighted in Five Oral Presentations at ICAAC Conference FOSTER CITY, Calif.--(BW HealthWire)--Sept. 23, 1998-- Gilead Sciences , Inc. (Nasdaq:GILD - news) announced today the completion of enrollment in three clinical studies of PREVEON(R) (adefovir dipivoxil) and the conclusion of a fourth stu
DURHAM, N.C.--(BUSINESS WIRE)-- Sept. 16, 1998--Trimeris, Inc. (NASDAQ: TRMS) announced today that patient selection and dosing have begun in its 28-day Phase II clinical trial for T-20. The trial will assess the optimal dosing for T-20 and the effect of T-20 on viral load in HIV patients. The protocol for this trial (
CHICAGO--(BUSINESS WIRE)--September 15, 1998--The Chicago Center for Clinical Research, Tuesday will begin inoculating volunteers in the North American trial of AIDSVAX, the first-ever vaccine against HIV to be tested in Phase III clinical trials. The clinic is one of the first to participate in the trial sponsored by
FOSTER CITY, Calif.--(BW HealthWire)--Sept. 4, 1998-- Gilead Sciences , Inc. (NASDAQ:GILD) announced today that it has begun enrolling patients in a Phase II study to evaluate the oral prodrug of PMPA (oral PMPA) for the potential treatment of human immunodeficiency virus (HIV) infection. Study Design The Phase
LOS ANGELES--(BUSINESS WIRE)--Sept. 3, 1998--City Report Shows Two-thirds with AIDS Surveyed Experience Homelessness While Millions Sit Unspent in City Coffers Activists Call for Federal Investigation, Adoption of AIDS Housing Bill of Rights AIDS Healthcare Foundation announced that while Mayor of L.A. Richard Riordan
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sept. 3, 1998--Dr. Donald P. Francis, President of VaxGen Inc., today issued the following statement regarding the deaths of Jonathan Mann and Mary Lou Clements-Mann in the Swissair crash: For me, this is a deep personal loss. I have known and admired both Jonathan Mann and
BERKELEY, Calif.--(BUSINESS WIRE)--Aug. 26, 1998--Calypte Biomedical Corporation (NASDAQ: CALY - news) announced today that six leading U.S. life insurance companies have begun applicant assessment using Calypte s complete Human Immunodeficiency Virus Type 1 (HIV-1) urine test system. In addition, company executives sa
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 30, 1998-- Shaman Pharmaceuticals, Inc. (NASDAQ:SHMN) announced today positive, statistically significant results from two separate Phase II dose optimization studies of SP-303/Provir(TM) in acute watery diarrhea patients from two different populations. Both studies we
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 30, 1998--The Center for Immunization Research at the Johns Hopkins University School of Hygiene and Public Health today will begin inoculating volunteers in the North American trial of AIDSVAX, the first-ever vaccine against HIV to be tested in Phase III human clinica
VERNON, Conn.--(BW HealthWire)--July 14, 1998--Bio-Plexus, Inc. (NASDAQ:BPLX), designer, developer, manufacturer, and marketer of safety medical products under the PUNCTUR-GUARD(R) name, today commented on California s Occupational Safety and Health Administration s proposed new regulations requiring the use of safety
SAN DIEGO--(BW HealthWire)--July 13, 1998--Ligand (LYE-gand) Pharmaceuticals Incorporated (NASDAQ:LGND) has announced that the company s New Drug Application (NDA) for Panretin(R) gel (alitretinoin) 0.1% for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi s sarcoma (KS) has been accepted
FARMINGDALE, N.Y.--(BUSINESS WIRE)--July 13, 1998--Enzo Biochem, Inc. (ASE:ENZ), announced today that it has initiated Phase I human clinical trials of HGTV43, a genetic antisense-based therapeutic product designed to treat HIV-1 infected individuals. This product has been developed to protect human immune cells agains
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--July 8, 1998--The Center for Vaccine Development at St. Louis University School of Medicine Wednesday will begin inoculating volunteers in the North American trial of AIDSVAX, the first-ever vaccine against HIV to be tested in Phase III human clinical trials. The North American tri
GENEVA, Switzerland--(BUSINESS WIRE)--July 2, 1998--U.S. Bioscience, Inc. (AMEX:UBS - news) today announced that data from the National Cancer Institute (NCI) sponsored Phase I clinical trial of its novel anti-retroviral agent, lodenosine (FddA), were presented during the 12th World AIDS Conference in Geneva, Switzerla
SANTA MONICA, Calif.--(BW HealthWire)--July 1, 1998--Specialty Laboratories has been selected to perform the HIV testing to support VaxGen Inc. s U.S. Phase III HIV-1 vaccine trial. Earlier this month, the Food and Drug Administration authorized VaxGen to go ahead with this large-scale prevention study, involving appro
SALT LAKE CITY--(BW HealthWire)--July 1, 1998--In response to an increasing number of calls from patients reporting problems associated with managed care s restrictive drug formularies, the International Patient Advocacy Association (IPAA) is launching a first-of-its-kind outreach effort to identify individuals who hav
FOSTER CITY, Calif.--(BW HealthWire)--July 1, 1998-- Gilead Sciences , Inc. (NASDAQ:GILD) announced today the presentation of data from a Phase II/III clinical trial of PREVEON(TM) (adefovir dipivoxil) demonstrating statistically significant, durable decreases in levels of HIV RNA for 48 weeks. These results, from Stud
EMERYVILLE, Calif.--(BW HealthWire)--July 1, 1998--Chiron Corporation (NASDAQ:CHIR) today provided an update on its HIV product development activities in both therapeutics and vaccines. In the therapeutics area, Chiron is investigating the use of its proprietary biologic, interleukin-2 ( IL-2 ), fo
GENEVA--(BUSINESS WIRE)--July 1, 1998-- Procept, Inc. (Nasdaq:PRCTC) today presented findings at the 12th World AIDS Conference in Geneva showing that its vaginal microbicide, PRO 2000 Gel, may provide protection against a number of sexually transmitted diseases. In a poster presentation, Procept scientists and colleag
ALAMEDA, Calif.--(BW HealthWire)--June 29, 1998--Chiron Informatics, a business unit of Chiron Corporation (NASDAQ:CHIR), will introduce HIV PromptChart(TM), a care management software tool, at the 12th Annual International AIDS Conference in Geneva. The first in a class of web-based applications, PromptChart creates,
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--June 29, 1998-- Gryphon Sciences announced today that a chemically synthesized protein analogue has been shown to be an extremely potent inhibitor of HIV infection in the hu-PBL-SCID mouse model for AIDS. The results were presented in Geneva at the International AIDS Confer
NEW YORK--(BW HealthWire)--June 26, 1998--The world received an important tool in the fight against AIDS with the U.S. Food and Drug Administration s recent approval of the first complete urine test system for HIV-1. The highly accurate test, invented by researchers at New York University School of Medicine, promises t
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--June 23, 1998--The Philadelphia FIGHT clinic today will begin inoculating the first volunteers in the North American trial of AIDSVAX, the first-ever Phase III trials of a vaccine against HIV-1. The trial, which eventually will include 5,000 volunteers at high risk for HIV
HOFFMAN ESTATES, Ill.--(BW HealthWire)--June 23, 1998-- Home Access Health, the maker of Home Access Express(R) and Home Access(R), the only FDA approved and doctor recommended HIV at-home tests, will offer its professional telephone consultation service for people interested in how to discuss HIV testing with a sexual
NEW YORK--(BW HealthWire)--June 22, 1998--In the July issue of OUT, senior editor Elise Harris, addresses the little known long-term side effects of protease inhibitors-the much hyped miracle drugs used to fight the AIDS epidemic-and finds that they are more than skin deep. Harris investigation finds that lipodystrophy
STANFORD, Calif.--(BW HealthWire)--June 18, 1998--A mathematical model devised by Stanford researchers suggests that vaccines against the AIDS-causing virus could save money, extend lives and prevent deaths even if those vaccines are only moderately effective in preventing or treating the infection. The researchers str
SAN DIEGO--(BW HealthWire)--June 18, 1998--Americans are not well informed about sexually transmitted diseases (STDs). So say 92 percent of physicians responding to a survey sponsored by Gen-Probe during the recent American College of Obstetricians and Gynecologists (ACOG) annual conference in New Orleans. Even more st
FOSTER CITY, Calif.--(BW HealthWire)--June 15, 1998--People with HIV disease and healthcare professionals from around the world will be able to view actual sessions from the 12th World AIDS Conference via the World Wide Web (WWW), according to organizers of this global meeting. The Webcast (webcast.aids98.org) will be
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--June 9, 1998-- Chemical protein synthesis illuminates vital target for new AIDS therapies Gryphon Sciences today announced the publication of the first crystal structure of the protein `SDF-1 alpha , the unique ligand for the HIV-1 co-receptor in human T-cells. The structur
SAN FRANCISCO--(BUSINESS WIRE)--June 8, 1998--The NAMES Project Foundation, sponsor of the International AIDS Memorial Quilt issued a call today for new Quilt panels to be added to the massive fabric monument commemorating individuals killed by HIV disease. According to the new Executive Director, Andy Ilves, the decli
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) June 3, 1998 -- VaxGen , Inc. today said the U.S. Food and Drug Administration has given permission for the start of Phase III clinical trials of the company s AIDSVAX vaccine against HIV, the virus that causes AIDS, marking the first time an HIV vaccine will be evaluated in
BERKELEY, Calif.--(BW HealthWire)--June 2, 1998--The development of new drugs is a lengthy, complex and costly process. It can also prove profitable; for example, more than 40,000 prescriptions for the new drug Viagra were written in just one week. But what process does a drug like Viagra go through before it can be pr
SAN DIEGO--(BW HealthWire)--May 28, 1998--A study published in the May 28 issue of the Journal of Clinical Psychiatry demonstrates that Prozac (fluoxetine hydrochloride) in combination with group therapy is more effective than group therapy alone in treating HIV-positive patients diagnosed with major depression. The st
Stanford University researchers will announce Sunday the results of a study showing that patients previously treated with multiple HIV drugs can develop full resistance to all currently available treatment combinations. The findings will be published in the June 1 issue of Annals of Internal Medicine, one day after 2,5
LAS VEGAS--(BUSINESS WIRE)--May 26, 1998--Steroidogenesis Inhibitors International (OTC/BB:STGI - news), makers of ANTICORT, the first drug developed specifically to counteract the immunodestructive effects of the hormone cortisol, Tuesday announced that it has submitted an investigational drug application to the Comis
SACRAMENTO, Calif.--(BW HealthWire)--May 20, 1998--Following testimony from the San Francisco AIDS Foundation and Project Inform, the California Assembly and Senate Budget Subcommittees today approved $126.2 million in funding for California s AIDS Drug Assistance Program (ADAP). ADAP, which is funded jointly by the st
DUBLIN, Ohio--(BW HealthWire)--May 19, 1998--Neoprobe Corporation (NASDAQ/NMS:NEOP - news) today announced the May publication of two peer-reviewed journal articles relating to the company s developing activated cellular therapy technology for HIV/AIDS. Results of the preclinical studies formed the basis of the company
REDWOOD CITY Calif.--(BW HealthWire)--May 15, 1998--SUGEN, Inc. (NASDAQ:SUGN) announced today that it is initiating a Phase I/II study to investigate the safety and efficacy of SU5416 in patients with Kaposi s sarcoma who have failed currently available therapy. The study will be conducted at five U.S. medical centers
PISCATAWAY, N.J.--(BUSINESS WIRE)--May 13, 1998--Enzon, Inc. (NASDAQ:ENZN) announced today that its marketing partner, Rhone-Poulenc Rorer Pharmaceuticals, Inc. (RPR) has expanded its license agreement to sell Enzon s Pegaspargase product in the Pacific Rim. RPR currently sells Pegaspargase under the trade name ONCASPA
ATLANTA--(BUSINESS WIRE)--May 11, 1998--Community Prescription Service in combination with AID Atlanta, AIDS Survival Project, Sister Love, Aid Gwinette and Project Azuka is proud to sponsor Positive Choices: A Treatment Workshop by and for Women living with HIV. The meeting will take place on Saturday, May 16th from 1
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--May 11, 1998-- IMMUNE RESEARCH (VSE:IMM.) At the request of the Vancouver Stock Exchange the Company reports that the study of its proprietary monoclonal antibody 1F7 in infected macaque monkeys as a model of HIV disease is in progress and there are no material changes in t
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--May 7, 1998-- Shaman Pharmaceuticals, Inc. (NASDAQ: SHMN) announced today that the U.S. Food and Drug Administration ( FDA ) had formally notified the company that its anti-diarrheal compound SP-303/Provir(TM), currently in Phase III clinical trials, has received a Fast Tr
SAN FRANCISCO--(BW HealthWire)--May 4, 1998-- Urging a renewed commitment to the HIV epidemic in the United States , the SF AIDS Foundation will join 400 community advocates in Washington, D.C. to demand increased funding for the full scope of federal HIV/AIDS programs as part of AIDSWatch 98 from May 3-5. The pa
SAN FRANCISCO--(BW HealthWire)--May 4, 1998--Urging a renewed commitment to the HIV epidemic in the United States , the SF AIDS Foundation will join 400 community advocates in Washington, D.C. to demand increased funding for the full scope of federal HIV/AIDS programs as part of AIDSWatch 98 from May 3-5. The par
BOSTON--(BW HealthWire)--April 30, 1998-- Chelsea, Mass. native Warren Alpert, chairman of Warren Equities, Inc., today bestowed the Tenth Annual Warren Alpert Foundation Prize to Dr. Robert Gallo of the University of Maryland at Baltimore and Dr. Luc Montagnier of Queens College, Flushing, N.Y. and Pasteur Institute,
SAN FRANCISCO--(BW HealthWire)--April 23, 1998--A coalition of AIDS and needle exchange activists will confront Health and Human Services Secretary Donna Shalala Friday, April 24, when she appears at the inauguration ceremony for UC Berkeley Chancellor Robert Berdahl, to be held at Zellerbach Hall on the UC Berkeley ca
TORONTO--(BUSINESS WIRE)--April 21, 1998--Novopharm Biotech In(TSE:NVO.) Novopharm Biotech Inc. announced that it has submitted an Investigational New Drug Application with the US Food and Drug Administration to conduct Phase IB/II clinical trials of GPI-2A, the Company s lead antisense product targeted for the treatme
WASHINGTON--(BW HealthWire)--April 21, 1998--The following is a statement by the Presidential Advisory Council On HIV/AIDS in response to the announcement by the Secretary of Health and Human Services regarding needle exchange programs: -0- The Presidential Advisory Council on HIV/AIDS welcomes Secretary of Health and
BALTIMORE--(BUSINESS WIRE)--April 21, 1998--A vaccine pairing a genetically altered, harmless canarypox virus, and a genetically engineered piece of the HIV protein coat, induce immune system activity against laboratory strains of HIV better than either vaccine alone, according to a Johns Hopkins School of Public Healt
SAN FRANCISCO--(BUSINESS WIRE)--April 20, 1998--Health and Human Services Secretary Donna Shalala has announced today her finding that needle exchange programs decrease the spread of HIV/AIDS and do not lead to increased drug use. In spite of this determination, however, Secretary Shalala will not make any federal fund
SAN FRANCISCO--(BW HealthWire)--April 17, 1998--AIDS specialists from 38 different nations will convene in San Francisco this weekend for a first-ever workshop dedicated to developing realistic steps that Third World countries can take to stem the HIV/AIDS pandemic. Unlike other international meetings, this workshop wi
FOSTER CITY, Calif.--(BW HealthWire)--April 6, 1998-- Gilead Sciences , Inc. (NASDAQ:GILD) announced today that its preliminary analysis of a Phase II/III study indicates that treatment of HIV-infected patients with PREVEON(TM) (adefovir dipivoxil) in combination with other antiretroviral therapies resulted in a statis
FOSTER CITY, Calif.--(BW HealthWire)--April 2, 1998-- Gilead Sciences , Inc. (NASDAQ:GILD) announced today that it has broadened the entry criteria of its expanded access program for PREVEON(TM) (adefovir dipivoxil), for the treatment of human immunodeficiency virus (HIV) infection, to include patients in need of new t
FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 31, 1998--Enzo Biochem, Inc. (AMEX:ENZ) announced today that its wholly owned subsidiary, Enzo Therapeutics, has received clearance from the Food and Drug Administration ( FDA ) for an Investigational New Drug application (IND) to initiate human clinical testing of Enzo s newly
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--March 30, 1998-- Shaman Pharmaceuticals, Inc. (NASDAQ:SHMN) announced today it has begun enrollment in its pivotal Phase III clinical trial for SP-303/Provir(tm), for the treatment of diarrhea in patients with AIDS. This double-blind, placebo controlled study is planned to
SEATTLE--(BW HealthWire)--March 25, 1998--The U.S. Food and Drug Administration has granted Glyde USA Inc. clearance to market Sheer Glyde Dams(TM), a 10 x 6, silky thin sheet of scented, natural latex, when used properly, may help reduce the risk of catching or spreading many sexually transmitted diseases (STDs). Gl
BUSINESS WIRE; Thursday, March 19, 1998, 07:31 EST
DURHAM, N.C.--(BUSINESS WIRE)--March 19, 1998--Trimeris, Inc. (NASDAQ:TRMS) announced today that it has signed a letter of intent with the DuPont Merck Pharmaceutical Company to conduct an advanced HIV patient trial using Sustiva (tm) ( efavirenz ), a on
(ADVANCE) SACRAMENTO, Calif.--(BUSINESS WIRE)--March 19, 1998-- The California Department of Health Services Office of AIDS will launch the first-ever long distance calling card campaign aimed at reducing the spread of HIV. The state will distribute 50,000 free 10-minute calling cards, which play an AIDS prevention mes
WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--March 18, 1998--The Being Alive/West Hollywood HIV Day Program is offering Wednesday ALIVE, a new vocational services program for people with AIDS who are interested in returning to work. Wednesday ALIVE services are available every Wednesday from 11 a.m. to 4 p.m. at the HIV Da
BUSINESS WIRE; Monday, March 16, 1998, 4:47 P.M. EST
SAN FRANCISCO--(BW HealthWire)--March 16, 1998--Three prominent AIDS-treating physicians will conduct a national dialogue on Choosing the Right HIV Treatment Strategy with participants of BETALIVE! Presented by the San Francisco AIDS Foundation, this free national telephone conference call for people with HIV/AIDS will
BUSINESS WIRE; Thursday, March 12, 1998, 6:25 am PST
TORONTO--(BUSINESS WIRE)--March 12, 1998--Dimethaid Research (TSE:DMX.) released abstracts of three independent research studies on the platform immune modulator, WF10, which suggests potential benefits in the treatment of HIV/AIDS. The WF10 data will be presented at the HIV Pathogenesis conference (Keystone Symposia o
LOS ANGELES--(BUSINESS WIRE)--March 11, 1998--Project New Hope announced the grand opening and dedication of the Jack H. Plimpton New Hope Apartments. The ceremony will be held Friday, March 20, from 3 p.m. to 7 p.m. at 2301 Brier Ave., Los Angeles, in the Silverlake district. The dedication will be followed by a sit-d
SAN FRANCISCO--(BW HealthWire)--March 2, 1998--A UC San Francisco study has found that capsaicin, a derivative of hot chili peppers, may significantly reduce chronic, debilitating nerve pain associated with a range of diseases when used in high doses. The study found that seven out of ten patients who suffered from deb
DUBLIN, Ireland--(BW HealthWire)--February 26, 1998--TRINITY BIOTECH PLC (Nasdaq: TRIBY) is pleased to announce the successful acquisition of a Malaysian government tender by BIO-LINK Sendirian Berhad for the Uni-Gold(tm) HIV rapid test. The Uni-Gold(tm) HIV rapid test will be utilized in a government HIV screening pro
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 18, 1998--DynaGen Inc. (NASDAQ:DYGN)(BSE:DYG) today announced that it has received a Notice of Allowance from the U.S. Patent Office for its patent application covering the use of its immunomodulator (ImmuDyn(TM)) in the treatment of HIV/AIDS. ImmuDyn is a proprietary lipid prepa
LAS VEGAS--(BW HealthWire)--Feb. 17, 1998--The stress hormone cortisol is now believed to be the cause of bizarre and severe side effects found among AIDS patients treated with protease inhibitors , the newest anti-HIV drugs. The side effects were reported for the first time publicly at the Fifth Conference on Retrovir
Manhunt: Dateless in San Francisco to feature provocative & humorous video, the San Francisco Gay Men s Chorus, and 150 gay & bisexual men discussing dating, relationships and body image WHAT: The San Francisco AIDS Foundation s Gay Life program -- a groundbreaking new HIV prevention program that focuses on th
VANCOUVER, Wash.--(BUSINESS WIRE)--Feb. 5, 1998--Saliva Diagnostic Systems, Inc. (Nasdaq: SALV - news, SALVW - news) today announced that arrangements have been made to begin the assembling and packaging of its test kits in the United Kingdom where all of Saliva Diagnostic Systems rapid test kits have been approved. In
SALT LAKE CITY--(BW HealthWire)--Feb. 4, 1998--Marine Research USA Inc., ( Marine ) an 80 percent owned subsidiary of ABS Group Inc. (OTC BB:ADBS - news) has received initial positive results from a study of HIV/AIDS patients in Melbourne, Australia which is sponsored by the Victorian AIDS Council in cooperation with M
CHICAGO--(BUSINESS WIRE)--Feb. 4, 1998-- Why Blacks Fear Government Medical Programs, Infamous Tuskegee Study (1932-72) Created Legacy of Distrust Despite dramatic advances in the fight against HIV/AIDS, African-Americans continue to suffer disproportionately - at least in part - because they don t trust government med
(Advance for release 9 a.m. EST Feb. 4.) STANFORD, Calif.--(BW HealthWire)--Feb. 3, 1998--HIV strains that have developed resistance to a wide range of antiviral drugs constitute the gravest challenge now facing AIDS researchers in the battle against this deadly virus. Two new studies by researchers at Stanford offer m
BERKELEY, Calif.--(BW HealthWire)--Feb. 3, 1998--Besides preventing HIV from killing T-cells, anti-retroviral treatments may increase the body s ability to generate new cells in some patients, according to recent data from a new diagnostic technique developed by UC Berkeley and UC San Francisco researchers. The techniq
CHICAGO--(BW HealthWire)--Feb. 2, 1998-- To Coincide With Completion of Presentation at 5th Conference on Retroviruses and Opportunistic Infections UCSF researchers are reporting a dramatic decline in several common opportunistic infections in HIV-infected patients at San Francisco General Hospital. Further studies mus
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 2, 1998-- Procept, Inc. (Nasdaq:PRCT - news) today is presenting the results of its second Phase I clinical trial of PRO 2000 Gel at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago. PRO 2000 Gel, the Company s lead drug candidate, is designed as a femal
NEWTOWN, Pa.--(BW HealthWire)--Jan. 27, 1998--More than two-thirds of patients seeking treatment for HIV are receiving triple antiretroviral therapy, according to the health care consulting firm Scott-Levin. Scott-Levin s HIV Therapy Audit for the third quarter of 1997 shows: -- 70% of patients receiving triple therapy
SAN FRANCISCO--(BW HealthWire)--Jan. 26, 1998--A study by the UCSF Center for AIDS Prevention Studies (CAPS) has found that HIV treatment decisions are not made lightly and that persons with HIV disease and their caregivers take a thoughtful and cautious approach in determining whether or not multi-drug therapy is appr
FOSTER CITY, Calif.--(BW HealthWire)--Jan. 26, 1998-- Gilead Sciences , Inc. (NASDAQ:GILD) announced today that data from a Phase I/II study of the oral formulation of PMPA, which is being developed for the treatment of HIV, will be presented at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago
SOUTH SAN FRANCISCO, Calif.--(BW HeathWire)--Jan. 20, 1998-- Gryphon Sciences today announced that Gryphon s chemically synthesized proteins played a key role in obtaining important data reported in the January 16 issue of Science. This Science paper is the latest in a series of fundamental biological discoveries enabl
LOS ANGELES--(BUSINESS WIRE)--Jan. 16, 1998--AIDS Healthcare Foundation s (AHF s) ability to communicate cutting-edge information about AIDS and its own programs and services took an exponential leap forward in late December with the launch of its Web site, that has been in development since April of last year. The sit
BERKELEY, Calif.--(BW HealthWire)--Jan. 16, 1998--Our understanding of how the AIDS virus works and how to effectively treat it continues to change at a rapid pace -- often as quickly as month to month. Given this fact and the fact that the battle to subdue AIDS is far from over, education regarding the disease is as c
WASHINGTON--(BW HealthWire)--Jan. 14, 1998--The National AIDS Fund has announced plans to distribute free at-home HIV tests to the Fund s community partners in 15 states following a successful World AIDS Day promotion sponsored by Home Access Health Corporation. Home Access Health, the leader in telemedicine providing
DUBLIN, Ohio--(BW HealthWire)--Jan. 13, 1998--Neoprobe Corporation (NASDAQ/NMS:NEOP) today announced the initiation of patient enrollment in a Phase I trial to investigate the use of activated cellular therapy (ACT) with patients co-infected with HIV/AIDS and chronic active hepatitis B or C.
NEWTOWN, Pa.--(BW HealthWire)--Jan. 12, 1998--The unique status of AIDS has led to a seeming paradox in the way pharmaceutical manufacturers market HIV therapies to managed care organizations, according to the latest analysis from the health care consulting firm Scott-Levin. Almost all HIV therapies are on managed care
OLYMPIA, Wash.--(BUSINESS WIRE)--Jan. 9, 1998--A 12-member task force will present recommendations on HIV reporting Tuesday, Jan. 13 to the Governor s Advisory Council on HIV/AIDS (GACHA). Among other findings, task force members agreed that the current AIDS surveillance system is obsolete as an accurate measure of the
DURHAM, N.C.--(BUSINESS WIRE)--Jan. 9, 1998--Trimeris Inc. (NASDAQ: TRMS) today announced that it has initiated a Phase II clinical trial for T-20, a new class of anti-viral fusion-inhibiting drugs which block HIV infection. The Phase II study will determine both the optimal dosing for T-20 and the feasibility of its a
LEXINGTON, Ky.--(BW HealthWire)--Jan. 8, 1998--The Company announces the publication of encouraging results from a study reported in the latest edition of The Proceedings of the National Academy of Science USA . Vol. 95 pp.276-281, January 6, 1998. The article describes the stimulation of HIV-1 antibodies in SHIV(IIIB)
(ADVANCE) BALTIMORE--(BW HealthWire)--Jan. 6, 1998--Researchers at the Johns Hopkins School of Public Health have demonstrated that guidelines used to indicate when combination antiretroviral therapy should be initiated with someone who has HIV infection are appropriate for African-Americans and for injection drug user
BUSINESS WIRE; Tuesday, January 6, 1998, 08:30 EST
WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jan. 6, 1998--U.S. Bioscience Inc. (AMEX:UBS) Tuesday announced the signing of a Cooperative Research and Development Agreement (CRADA) between the company and the National Cancer Institute for clinical development of lodenosine (formerly FddA), an anti-HIV compound. Under an ex
This information is designed to support, not replace, the relationship that exists between you and your doctor.